News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,229 Results
Type
Article (13867)
Company Profile (294)
Press Release (246068)
Section
Business (79321)
Career Advice (148)
Deals (13179)
Drug Delivery (32)
Drug Development (50285)
Employer Resources (31)
FDA (5669)
Job Trends (5111)
News (144056)
Policy (10013)
Tag
Academia (901)
Alliances (21466)
Alzheimer's disease (736)
Approvals (5643)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4496)
Biotechnology (242)
Breast cancer (65)
Cancer (691)
Cardiovascular disease (62)
Career advice (129)
CAR-T (56)
Cell therapy (175)
Clinical research (39799)
Collaboration (237)
Compensation (97)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (790)
Diabetes (73)
Diagnostics (1200)
Earnings (28974)
Events (46829)
Executive appointments (192)
FDA (5958)
Funding (243)
Gene editing (55)
Gene therapy (145)
GLP-1 (300)
Government (1063)
Healthcare (6531)
Infectious disease (1036)
Inflammatory bowel disease (94)
IPO (7177)
Job creations (859)
Job search strategy (125)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6099)
Metabolic disorders (223)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (946)
Obesity (122)
Opinion (91)
Parkinson's disease (61)
Patents (51)
People (24975)
Pharmaceutical (49)
Phase I (13999)
Phase II (18510)
Phase III (11735)
Pipeline (320)
Postmarket research (846)
Preclinical (5922)
Radiopharmaceuticals (204)
Rare diseases (167)
Real estate (1409)
Regulatory (8201)
Research institute (930)
Southern California (865)
Startups (1963)
United States (7578)
Vaccines (159)
Weight loss (76)
Date
Today (71)
Last 7 days (520)
Last 30 days (2277)
Last 365 days (20681)
2024 (18958)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16826)
Australia (2837)
California (2142)
Canada (710)
China (161)
Colorado (79)
Connecticut (84)
Europe (36237)
Florida (226)
Georgia (62)
Illinois (125)
Indiana (54)
Kansas (55)
Maryland (298)
Massachusetts (1698)
Michigan (48)
Minnesota (93)
New Jersey (542)
New York (608)
North Carolina (398)
Northern California (946)
Ohio (78)
Pennsylvania (425)
South America (207)
Southern California (865)
Texas (226)
Washington State (217)
260,229 Results for "appili therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2024 (“FYE 2024”), and provided an update on the Company’s strategy for fiscal 2025.
June 25, 2024
·
10 min read
Press Releases
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
October 10, 2024
·
8 min read
Press Releases
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
November 15, 2024
·
9 min read
Press Releases
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
November 7, 2024
·
4 min read
Press Releases
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
October 17, 2024
·
5 min read
Business
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 17, 2024
·
2 min read
Press Releases
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
November 1, 2024
·
6 min read
Press Releases
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
October 10, 2024
·
10 min read
Press Releases
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 31, 2024
·
4 min read
Business
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023.
February 13, 2024
·
7 min read
1 of 26,023
Next
